Transporter-mediated uptake into cellular compartments

References

• Abraham EH, Shrivastav B, Salikhova AY, Sterling KM, Johnston N, Guidotti G, Scala S, Litman T, Chan KC, Arceci RJ, et al. Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes. Blood Cells, Molecular and Disease 2001; 27: 181–200
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Tsuruo T, Gupta S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. Journal of Clinical Immunology 1997; 17: 448–454
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR, Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. Niemann–Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201–1204
   PubMed Web of Science ®Google Scholar
• Anderle P, Huang Y, Sadee W. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. European Journal of Pharmaceutical Sciences 2004; 21: 17–24
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, Van Vliet EA, Scheffer GL, Scheper RJ, van der Valk P, Baayen JC, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004; 45: 441–451
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469–497
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical Pharmacology and Therapeutics 2002; 72: 685–691
   PubMed Web of Science ®Google Scholar
• Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clinical Pharmacology and Therapeutics 2005; 78: 154–167
   PubMed Web of Science ®Google Scholar
• Barr WH, Zola EM, Candler EL, Hwang SM, Tendolkar AV, Shamburek R, Parker B, Hilty MD. Differential absorption of amoxicillin from the human small and large intestine. Clinical Pharmacology and Therapeutics 1994; 56: 279–285
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood–brain barrier. Experimental Biology and Medicine (Maywood) 2005; 230: 118–127
   PubMed Web of Science ®Google Scholar
• Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Science 2002; 71: 163–169
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacology and Therapy 2006; 112: 457–473
   PubMed Web of Science ®Google Scholar
• Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reproductive Toxicology 2006; 22: 400–410
   PubMed Web of Science ®Google Scholar
• Chan KK, Buch A, Glazer RD, John VA, Barr WH. Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharmaceutical Research 1994; 11: 432–437
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 2004; 21: 25–51
   PubMed Web of Science ®Google Scholar
• Chandra P, Brouwer KL. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research 2004; 21: 719–735
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735–2739
   PubMed Web of Science ®Google Scholar
• Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. Journal of Biological Chemistry 2001; 276: 33747–33754
   PubMed Web of Science ®Google Scholar
• Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Pharmaceutical Reviews 2005; 78: 342–350
   Google Scholar
• Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmaceutical Reviews 2006; 58: 244–258
   PubMed Web of Science ®Google Scholar
• Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, Murcia-Lopez A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Annals of Pharmacotherapy 2005; 39: 533–537
   PubMed Web of Science ®Google Scholar
• Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmaceutical Reviews 2006; 58: 140–161
   PubMed Web of Science ®Google Scholar
• Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. Journal of Biological Chemistry 2005; 280: 12710–12720
   PubMed Web of Science ®Google Scholar
• Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Bohm M, Warzok R, Kerb R, Brinkmann U, Schaeffeler E, et al. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. American Journal of Pathology 2003; 163: 1567–1577
   PubMed Web of Science ®Google Scholar
• DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food and Chemical Toxicology 2001; 39: 209–228
   PubMed Web of Science ®Google Scholar
• Doherty MM, Charman WN. The mucosa of the small intestine — how clinically relevant as an organ of drug metabolism?. Clinical Pharmacokinetics 2002; 41: 235–253
   PubMed Web of Science ®Google Scholar
• Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D. Over-expression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42: 1501–1506
   PubMed Web of Science ®Google Scholar
• Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729–2734
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clinical Pharmacology and Therapeutics 2002; 71: 11–20
   PubMed Web of Science ®Google Scholar
• Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood–brain barrier. Human Psychopharmacology 2005; 20: 149–153
   PubMed Web of Science ®Google Scholar
• El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates. Journal of Pharmacy and Pharmacology 2004; 56: 967–975
   PubMed Web of Science ®Google Scholar
• Eloranta JJ, Meier PJ, Kullak-Ublick GA. Coordinate transcriptional regulation of transport and metabolism. Methods in Enzymology 2005; 400: 511–530
   PubMed Web of Science ®Google Scholar
• Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. European Journal of Pharmaceutical Sciences 2006; 27: 501–517
   PubMed Web of Science ®Google Scholar
• Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. European Journal of Pharmaceutical Sciences 2006; 29: 269–277
   PubMed Web of Science ®Google Scholar
• Ezzet F, Wexler D, Statkevich P, Kosoglou T, Patrick J, Lipka L, Mellars L, Veltri E, Batra V. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. Journal of Clinical Pharmacology 2001; 41: 943–949
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002; 359: 30–36
   PubMed Web of Science ®Google Scholar
• Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, et al. Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro and in vivo. Journal of Clinical Investigation 2002; 110: 1309–1318
   PubMed Web of Science ®Google Scholar
• Fischer V, Einolf HJ, Cohen D. Efflux transporters and their clinical relevance. Mini Reviews in Medicinal Chemistry 2005; 5: 183–195
   PubMed Web of Science ®Google Scholar
• Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, De Haas M, Meijer CJ, Scheper RJ. Tissue distribution of the multidrug resistance protein. American Journal of Pathology 1996; 148: 1237–1247
   PubMed Web of Science ®Google Scholar
• Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. Journal of Immunology 2001; 166: 2451–2459
   PubMed Web of Science ®Google Scholar
• Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro–in vivo correlation. British Journal of Pharmacology 1996; 118: 1841–1847
   PubMed Web of Science ®Google Scholar
• Fricker G, Miller DS. Modulation of drug transporters at the blood–brain barrier. Pharmacology 2004; 70: 169–176
   PubMed Web of Science ®Google Scholar
• Fromm MF. Importance of P-glycoprotein at blood–tissue barriers. Trends in Pharmacological Sciences 2004; 25: 423–429
   PubMed Web of Science ®Google Scholar
• Fudio S, Carcas A, Pinana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. Journal of Clinical Pharmacology and Therapeutics 2006; 31: 393–396
   PubMed Web of Science ®Google Scholar
• Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. Annals of Internal Medicine 2004; 140: 671–672
   PubMed Web of Science ®Google Scholar
• Gallo JM, Li S, Guo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Research 2003; 63: 5114–5117
   PubMed Web of Science ®Google Scholar
• Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Jr, Dean DC, Detmers PA, et al. The target of ezetimibe is Niemann–Pick C1-Like 1 (NPC1L1). Proceedings of the National Academy of Sciences, USA 2005; 102: 8132–8137
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clinical Pharmacology and Therapeutics 2007; 81: 362–370
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Drug transport at the blood–brain barrier and the choroid plexus. Current Drug Metabolism 2004; 5: 95–108
   PubMed Web of Science ®Google Scholar
• Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clinical Pharmacology and Therapeutics 1996; 59: 541–549
   PubMed Web of Science ®Google Scholar
• Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clinical Pharmacology and Therapeutics 2006a; 80: 607–620
   PubMed Web of Science ®Google Scholar
• Grube M, Meyer Zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K, Rosskopf D, Eckel L, Bohm M, et al. Uptake of cardiovascular drugs into the human heart: Expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 2006b; 113: 1114–1122
   PubMed Web of Science ®Google Scholar
• Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochemical Pharmacology 2005; 70: 695–699
   PubMed Web of Science ®Google Scholar
• Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D’Aquila RT, De Gruttda, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. Journal of Infectious Diseases 2005; 192: 1931–1942
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Archive: European Journal of Physiology 2004; 447: 653–665
   PubMed Web of Science ®Google Scholar
• Hasannejad H, Takeda M, Narikawa S, Huang XL, Enomoto A, Taki K, Niwa T, Jung SH, Onozato ML, Tojo A, et al. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. European Journal of Pharmacology 2004; 499: 45–51
   PubMed Web of Science ®Google Scholar
• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 2005; 78: 260–277
   PubMed Web of Science ®Google Scholar
• Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arteriosclerosis, Thrombosis and Vascular Biology 2006; 26: 2433–2438
   PubMed Web of Science ®Google Scholar
• Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, Von Bergmann K, Eichelbaum M, Kivisto KT. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical Pharmacology and Therapeutics 2006; 79: 419–426
   PubMed Web of Science ®Google Scholar
• Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharmaceutical Research 2005; 22: 1559–1577
   PubMed Web of Science ®Google Scholar
• Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19: 2097–2102
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. Journal of Biological Chemistry 2000; 275: 30069–30074
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu X, Jia X, Chen J, Hu M. Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Current Drug Metabolism 2005; 6: 455–468
   PubMed Web of Science ®Google Scholar
• Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. AIDS 2001a; 15: 1353–1358
   PubMed Web of Science ®Google Scholar
• Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001b; 15: 675–681
   PubMed Web of Science ®Google Scholar
• Jonker JW, Buitelaar M, Wagenaar E, Van der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences, USA 2002; 99: 15649–15654
   PubMed Web of Science ®Google Scholar
• Jorajuria S, Dereuddre-Bosquet N, Naissant-Storck K, Dormont D, Clayette P. Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages. Antimicrobial Agents and Chemotherapy 2004; 48: 1889–1891
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics 2005; 78: 388–399
   PubMed Web of Science ®Google Scholar
• Katsura T, Inui K. Intestinal absorption of drugs mediated by drug transporters: Mechanisms and regulation. Drug Metabolism and Pharmacokinetics 2003; 18: 1–15
   PubMedGoogle Scholar
• Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clinical Pharmacology and Therapeutics 2006; 79: 186–196
   PubMed Web of Science ®Google Scholar
• Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. Journal of Pharmaceutical Sciences 1999; 88: 1281–1287
   PubMed Web of Science ®Google Scholar
• Kemper EM, Boogerd W, Thuis I, Beijnen JH, Van Tellingen O. Modulation of the blood–brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours?. Cancer Treatment Reviews 2004; 30: 415–423
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation 1998; 101: 289–294
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharmaceutical Research 2007; 24: 239–247
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. Journal of Pharmacology and Experimental Therapeutics 2003; 306: 703–708
   PubMed Web of Science ®Google Scholar
• Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, Kroemer HK. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: Relevance for physiology and pharmacotherapy. Clinical Pharmacokinetics 2007; 46: 449–470
   PubMed Web of Science ®Google Scholar
• Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Archives in Pharmacology 2006; 372: 432–443
   PubMed Web of Science ®Google Scholar
• Kopplow K, Letschert K, Konig J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Molecular Pharmacology 2005; 68: 1031–1038
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clinical Pharmacokinetics 2005; 44: 467–494
   PubMed Web of Science ®Google Scholar
• Krause MS, Oliveira LP, Jr, Silveira EM, Vianna DR, Rossato JS, Almeida BS, Rodrigues MF, Fernandes AJ, Costa JA, Curi R, et al. MRP1/GS-X pump ATPase expression: is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison with skeletal muscle cells?. Cell Biochemistry and Function 2007; 25: 23–32
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525–533
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322–342
   PubMed Web of Science ®Google Scholar
• Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Current Drug Metabolism 2004; 5: 109–124
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. Active efflux across the blood–brain barrier: role of the solute carrier family. NeuroRx 2005; 2: 73–85
   PubMedGoogle Scholar
• Kuypers DR. Benefit–risk assessment of sirolimus in renal transplantation. Drug Safety 2005; 28: 153–181
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology 2004; 57: 181–187
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clinical Pharmacology and Therapeutics 2007; 81: 194–204
   PubMed Web of Science ®Google Scholar
• Lee W, Kim RB. Transporters and renal drug elimination. Annual Reviews in Pharmacology and Toxicology 2004; 44: 137–166
   PubMed Web of Science ®Google Scholar
• Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, Keppler D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochemistry Journal 1996; 314(2)433–437
   PubMed Web of Science ®Google Scholar
• Lennernas H. Intestinal drug absorption and bioavailability: Beyond involvement of single transport function. Journal of Pharmacy and Pharmacology 2003; 55: 429–433
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clinical Pharmacology and Therapeutics 2003; 73: 192–198
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmacokinetics of acebutolol. British Journal of Clinical Pharmacology 2005; 60: 659–663
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005a; 2: 86–98
   PubMedGoogle Scholar
• Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews in Neuroscience 2005b; 6: 591–602
   PubMed Web of Science ®Google Scholar
• Ludescher C, Pall G, Irschick EU, Gastl G. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. British Journal of Haematology 1998; 101: 722–727
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical Pharmacology and Therapeutics 2006; 79: 427–439
   PubMed Web of Science ®Google Scholar
• Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clinical Pharmacokinetics 2001; 40: 573–585
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin–Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. Journal of Pharmacology and Experimental Therapeutics 2005; 314: 1059–1067
   PubMed Web of Science ®Google Scholar
• Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Williams I, Back DJ, Khoo SH. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. Journal of Antimicrobial Chemotherapy 2002; 50: 583–588
   PubMed Web of Science ®Google Scholar
• Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metabolism and Disposition 2007; 35: 590–594
   PubMed Web of Science ®Google Scholar
• Meissner K, Heydrich B, Jedlitschky G, Meyer zu SH, Mosyagin I, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, et al. The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. Journal of Histochemistry and Cytochemistry 2006; 54: 215–221
   PubMed Web of Science ®Google Scholar
• Meissner K, Jedlitschky G, Meyer zu SH, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004; 14: 381–385
   PubMedGoogle Scholar
• Meissner K, Kessler W, Meyer zu Schwabedissen H, Schuster K, Saalfeld K, Grube M, Buck A, Jedlitschky G, Maier S, et al. Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type cGMP export pump. 2007, Shock (accepted)
   Google Scholar
• Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. Journal of Histochemistry and Cytochemistry 2002; 50: 1351–1356
   PubMed Web of Science ®Google Scholar
• Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metabolism and Pharmacokinetics 2004; 19: 453–455
   PubMedGoogle Scholar
• Morimoto K, Ueda S, Seki N, Igawa Y, Kameyama Y. OATP-C (OATP1B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients. Clinical Pharmacology and Therapeutics 2005; 77: P21
   Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical Pharmacology and Therapeutics 2004; 75: 415–421
   PubMed Web of Science ®Google Scholar
• Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatric Neurology 2004; 31: 232–234
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics 2006; 80: 565–581
   PubMed Web of Science ®Google Scholar
• Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nature Genetics 1999; 21: 91–94
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics 2005a; 77: 468–478
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). British Journal of Clinical Pharmacology 2005b; 59: 602–604
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, Von Bergmann K, Eichelbaum M, Kivisto KT. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics 2005c; 15: 303–309
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429–440
   PubMedGoogle Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metabolism and Pharmacokinetics 2005; 20: 452–477
   PubMedGoogle Scholar
• Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. Journal of Pharmacology and Experimental Therapeutics 2004; 308: 438–445
   PubMed Web of Science ®Google Scholar
• Nutting DF, Kumar NS, Siddiqi SA, Mansbach CM. Nutrient absorption. Current Opinion in Gastroenterology 2002; 18: 168–175
   PubMed Web of Science ®Google Scholar
• Oerlemans R, Van der HJ, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, et al. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis and Rheumatism 2006; 54: 557–568
   PubMed Web of Science ®Google Scholar
• Ogawa K, Yumoto R, Hamada N, Nagai J, Takano M. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. Epilepsy Research 2006; 71: 76–87
   PubMed Web of Science ®Google Scholar
• Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. Journal of Pharmacology and Experimental Therapeutics 1999; 291: 778–784
   PubMed Web of Science ®Google Scholar
• Omoda K, Murakami T, Yumoto R, Nagai J, Maeda Y, Kiribayashi Y, Takano M. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. Journal of Pharmaceutical Sciences 2005; 94: 1685–1693
   PubMed Web of Science ®Google Scholar
• Oselin K, Mrozikiewicz PM, Pahkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. European Journal of Haematology 2003; 71: 119–123
   PubMed Web of Science ®Google Scholar
• Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, Siegmund W. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical Pharmacology and Therapeutics 2006a; 80: 477–485
   PubMed Web of Science ®Google Scholar
• Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clinical Pharmacology and Therapeutics 2006b; 79: 206–217
   PubMed Web of Science ®Google Scholar
• Oswald S, Koll C, Siegmund W. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (–/–) mice. Journal of Pharmaceutical Sciences 2007, (accepted)
   PubMed Web of Science ®Google Scholar
• Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. Journal of Pharmacology and Experimental Therapeutics 2006c; 318: 1293–1299
   PubMed Web of Science ®Google Scholar
• Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. Journal of HIV Therapy 2004; 9: 97–101
   PubMedGoogle Scholar
• Pauli-Magnus C, Meier PJ. Hepatocellular transporters and cholestasis. Journal of Clinical Gastroenterology 2005; 39: S103–S110
   PubMed Web of Science ®Google Scholar
• Petri N, Borga O, Nyberg L, Hedeland M, Bondesson U, Lennernas H. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 2006; 44: 71–79
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001; 12: 3557–3560
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: Evidence from microdialysis experiments in rats. Neuroscience Letters 2002; 327: 173–176
   PubMed Web of Science ®Google Scholar
• Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood–brain barrier of rats. Epilepsia 2001; 42: 1231–1240
   PubMed Web of Science ®Google Scholar
• Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Molecular Pharmacology 2003; 63: 1094–1103
   PubMed Web of Science ®Google Scholar
• Riffkin CD, Chung R, Wall DM, Zalcberg JR, Cowman AF, Foley M, Tilley L. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochemical Pharmacology 1996; 52: 1545–1552
   PubMed Web of Science ®Google Scholar
• Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics 2002a; 41: 751–790
   PubMed Web of Science ®Google Scholar
• Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics Journal 2002b; 2: 191–196
   PubMedGoogle Scholar
• Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics 2000; 68: 231–237
   PubMed Web of Science ®Google Scholar
• Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metabolism and Disposition 2005; 33: 518–523
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Molecular CA, Van Deemter L. P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996; 97: 2517–2524
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Van Deemter L, Molecular CA, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Journal of Clinical Investigation 1995; 96: 1698–1705
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clinical Pharmacology and Therapeutics 2004; 75: 455–463
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Medicine 1999; 5: 1048–1051
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics 2005; 77: 291–301
   PubMed Web of Science ®Google Scholar
• Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporters. American Journal of Physiology. Renal Physiology 2006; 290: F251–F261
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutic 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. Journal of Pharmacology and Experimental Therapeutics 2004; 311: 228–236
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences 2006; 27: 425–446
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics 2006; 112: 71–105
   PubMed Web of Science ®Google Scholar
• Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Canadian Journal of Cardiology 2006; 22: 141–144
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clinical Pharmacology and Therapeutics 2004; 76: 167–177
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999; 10: 3437–3441
   PubMed Web of Science ®Google Scholar
• Solbach TF, Konig J, Fromm MF, Zolk O. ATP-binding cassette transporters in the heart. Trends in Cardiovascular Medicine 2006; 16: 7–15
   PubMed Web of Science ®Google Scholar
• Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrobial Agents and Chemotherapy 1998; 42: 3157–3162
   PubMed Web of Science ®Google Scholar
• Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. European Journal of Pharmaceutical Sciences 2004; 21: 3–16
   PubMed Web of Science ®Google Scholar
• Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Archive: European Journal of Physiology 2007; 453: 611–620
   PubMed Web of Science ®Google Scholar
• Sugawara I, Akiyama S, Scheper RJ, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Letters 1997; 112: 23–31
   PubMed Web of Science ®Google Scholar
• Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Annals of Pharmacotherapy 2004; 38: 1631–1634
   PubMed Web of Science ®Google Scholar
• Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metabolism and Pharmacokinetics 2004; 19: 375–380
   PubMedGoogle Scholar
• Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. Journal of Human Genetics 2006; 51: 822–826
   PubMed Web of Science ®Google Scholar
• Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacology and Therapeutics 2006; 109: 137–161
   PubMed Web of Science ®Google Scholar
• Terada T, Inui K. Peptide transporters: Structure, function, regulation and application for drug delivery. Current Drug Metabolism 2004; 5: 85–94
   PubMed Web of Science ®Google Scholar
• Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. European Archives in Psychiatry and Clinical Neurosciene 2006; 256: 281–286
   PubMed Web of Science ®Google Scholar
• Torii M, Takiguchi Y, Izumi M, Fukushima T, Yokota M. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. International Journal of Pharmaceutics 2002; 233: 253–256
   PubMed Web of Science ®Google Scholar
• Torii M, Takiguchi Y, Saito F, Izumi M, Yokota M. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats. Journal of Pharmacy and Pharmacology 2001; 53: 823–829
   PubMed Web of Science ®Google Scholar
• Trauner M, Boyer JL. Bile salt transporters: Molecular characterization, function, and regulation. Physiology Review 2003; 83: 633–671
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Molecular Pharmacology 2001; 59: 405–414
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. Journal of Psychiatric Research 2003; 37: 179–185
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biology and Psychiatry 2003; 54: 840–846
   PubMed Web of Science ®Google Scholar
• Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood–brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380–387
   PubMed Web of Science ®Google Scholar
• Van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, Van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. Journal of the National Cancer Institute 1996a; 88: 994–999
   PubMed Web of Science ®Google Scholar
• Van Asperen J, Van Tellingen O, Schinkel AH, Beijnen JH. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics 1999b; 289: 329–333
   PubMed Web of Science ®Google Scholar
• Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. British Journal of Cancer 1999b; 79: 108–113
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clinical Pharmacokinetics 1995; 29: 404–430
   PubMed Web of Science ®Google Scholar
• Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): Possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochemical Pharmacology 1998; 56: 733–742
   PubMed Web of Science ®Google Scholar
• Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clinical Pharmacology and Therapeutics 2004; 75: 172–183
   PubMed Web of Science ®Google Scholar
• Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. International Journal of Neuropsychopharmacology 2004a; 7: 415–419
   PubMed Web of Science ®Google Scholar
• Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay DV. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 2004b; 29: 551–557
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berlin) 2006; 187: 415–423
   PubMed Web of Science ®Google Scholar
• Wang X, Baba M. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antiviral Chemistry and Chemotherapy 2005; 16: 213–216
   PubMedGoogle Scholar
• Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceutical Research 2005; 22: 728–735
   PubMed Web of Science ®Google Scholar
• Woodrow CJ, Krishna S. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cellular and Molecular Life Science 2006; 63: 1586–1596
   PubMed Web of Science ®Google Scholar
• Wu CP, Klokouzas A, Hladky SB, Ambudkar SV, Barrand MA. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochemistry and Pharmacology 2005a; 70: 500–510
   PubMed Web of Science ®Google Scholar
• Wu CP, Woodcock H, Hladky SB, Barrand MA. cGMP (guanosine 3′,5′-cyclic monophosphate) transport across human erythrocyte membranes. Biochemical Pharmacology 2005b; 69: 1257–1262
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 2005; 22: 11–23
   PubMed Web of Science ®Google Scholar
• Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. Journal of Biological Chemistry 1998; 273: 32776–32786
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Archives of Pharmacal Research 2005; 28: 249–268
   PubMed Web of Science ®Google Scholar
• Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, Fujimura A. Panipenem-betamipron and decreases in serum valproic acid concentration. Therapeutic and Drug Monitoring 1998; 20: 396–400
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: A preliminary study. Progress in Neuropsychopharmacology and Biological Psychiatry 2006; 30: 286–291
   PubMed Web of Science ®Google Scholar
• Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, Davis MA, Michaely P, Liu P, Willingham MC, Rudel LL. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. Journal of Biological Chemistry 2006; 281: 6616–6624
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. European Journal of Pharmaceutical Sciences 2006; 27: 447–486
   PubMed Web of Science ®Google Scholar
• Zhang J, Alston MA, Huang H, Rabin RL. Human T cell cytokine responses are dependent on multidrug resistance protein-1. International Immunology 2006a; 18: 485–493
   PubMed Web of Science ®Google Scholar
• Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, Tan ZR, Zhang WX, Yu BN, Wang D, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. British Journal of Clinical Pharmacology 2006b; 62: 567–572
   PubMed Web of Science ®Google Scholar
• Zhang Y, Berger SA. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemotherapy and Pharmacology 2003; 51: 407–414
   PubMed Web of Science ®Google Scholar
• Zhang YC, Benet LZ. The gut as a barrier to drug absorption — combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics 2001; 40: 159–168
   PubMed Web of Science ®Google Scholar
• Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 2005; 105: 2571–2576
   PubMed Web of Science ®Google Scholar
• Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metabolism and Disposition 2005; 33: 219–224
   PubMed Web of Science ®Google Scholar
• Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Molecular and Cellular Biology 2001; 21: 4188–4196
   PubMed Web of Science ®Google Scholar